Last reviewed · How we verify
MabCampath-1h
MabCampath-1h is a Monoclonal antibody (CD52 antagonist) Small molecule drug developed by University of British Columbia. It is currently in Phase 3 development for Chronic lymphocytic leukemia (CLL), B-cell lymphomas. Also known as: Alemtuzumab.
MabCampath-1h is a humanized monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
MabCampath-1h is an antibody that inhibits the CAMPATH-1 antigen. It is being studied in a clinical trial for the treatment of Relapsing Remitting Multiple Sclerosis.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MabCampath-1h |
|---|---|
| Also known as | Alemtuzumab |
| Sponsor | University of British Columbia |
| Drug class | Monoclonal antibody (CD52 antagonist) |
| Target | CD52 |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
The drug targets CD52, a glycoprotein expressed on B cells, T cells, and other lymphocytes. Upon binding, it triggers immune-mediated destruction of these cells, resulting in profound lymphocyte depletion. This mechanism is used therapeutically in conditions where reduction of pathogenic lymphocytes is beneficial, such as chronic lymphocytic leukemia and certain autoimmune disorders.
Approved indications
- Chronic lymphocytic leukemia (CLL)
- B-cell lymphomas
Common side effects
- Infusion reactions
- Lymphopenia
- Infections
- Anemia
- Thrombocytopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MabCampath-1h CI brief — competitive landscape report
- MabCampath-1h updates RSS · CI watch RSS
- University of British Columbia portfolio CI
Frequently asked questions about MabCampath-1h
What is MabCampath-1h?
How does MabCampath-1h work?
What is MabCampath-1h used for?
Who makes MabCampath-1h?
Is MabCampath-1h also known as anything else?
What drug class is MabCampath-1h in?
What development phase is MabCampath-1h in?
What are the side effects of MabCampath-1h?
What does MabCampath-1h target?
Related
- Drug class: All Monoclonal antibody (CD52 antagonist) drugs
- Target: All drugs targeting CD52
- Manufacturer: University of British Columbia — full pipeline
- Therapeutic area: All drugs in Oncology, Immunology
- Indication: Drugs for Chronic lymphocytic leukemia (CLL)
- Indication: Drugs for B-cell lymphomas
- Also known as: Alemtuzumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing